TruCytes™ Potency

A Scalable, Reproducible Alternative to Cell Line Targets for CAR-Based Potency Assays

Optimize Functional CAR-T Potency Readouts

These lyophilized, customizable cell mimics express clinically relevant antigens (e.g., CD19, BCMA) at controlled densities—enabling clear and consistent cytokine release without the hurdles of cell-line engineering, maintenance, or chain-of-custody.

Key Advantages of TruCytes Potency

Enables functional potency readouts aligned with MoA (e.g., IFN-γ secretion)
Delivers consistent, antigen-specific activation across runs and operators
Customizable to your CAR target and antigen density, supporting assay optimization and scalability
Accelerates assay qualification and lot release with ready-to-use, standardized targets

AVAILABLE NOW

Application Note

Following ISCT 2025 presentation, our full application note is now available. It details how TruCytes Potency cell mimics were evaluated compared with tumor cell lines. Data included demonstrates strong, sustained IFN-γ release, reduced nonspecific activation, and superior reproducibility.

Get your free copy below.

Where TruCytes Potency Makes a Difference

Assay Development

Tunable antigen density allows developers to modulate activation strength refining assay sensitivity

Quality Control

Precision-engineered manufacturing delivers consistent activation profiles across runs, sites, and operators

Tech Transfer

Consistent performance helps establish functional assays at new facilities with fewer bridging studies or delays

Let’s Design Your TruCytes Potency Solution.

Whether you’re exploring CD19, BCMA, or another CAR target, share a few details about your antigen and assay format. Our team will follow up promptly to discuss how TruCytes Potency can support your development goals.